Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SERENA-4
2023-503995-26-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Camizestrant + palbociclib with Anastrozole + palbociclib (2 arms). Primary endpoint: Progression-free survival. Planned start May 2021; status: authorised.
02
Drugs
camizestrantpalbociclibanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-503995-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503995-26-00.